Pharmacological inhibition of RAS overcomes FLT3 inhibitor resistance in FLT3-ITD+ AML through AP-1 and RUNX1

Search results

• Finished

  Understanding the rewiring of growth signalling in FLT3-ITD and RAS mutant leukaemias after treatment with FLT3 and RAS inhibitors

  Coleman, D. (Principal Investigator)

  The Royal Society

  1/12/22 → 29/02/24

  Project: Research Councils

  • Pharmacological Inhibitors 100%
  • Activator protein-1 (AP-1) 100%
  • FLT3 Inhibitor 100%
  • Runt-related Transcription Factor 1 (RUNX1) 100%
  • FLT3 Internal Tandem Duplication 100%

• Pharmaceutical targeting of RAS in Acute Myeloid Leukaemia with RAS mutations or FLT3-ITD

  Coleman, D. (Principal Investigator)

  LEUKAEMIA UK

  1/01/22 → 29/02/24

  Project: Research

  • Myeloid 100%
  • Gene Regulatory Network 95%
  • Acute Myeloid Leukemia 87%
  • Activator protein-1 (AP-1) 62%
  • Runt-related Transcription Factor 1 (RUNX1) 57%

• Finding therapeutic targets in FLT3-ITD AML using a systems biology approach

  Cockerill, P. (Co-Investigator) & Bonifer, C. (Principal Investigator)

  Medical Research Council

  1/09/19 → 31/12/23

  Project: Research Councils

  • Gene Regulatory Network 100%
  • Acute Myeloid Leukemia 94%
  • Transcription Factors 89%
  • Transcription Factor 79%
  • Runt-related Transcription Factor 1 (RUNX1) 78%